Table 1 Inclusion and exclusion criteria

Population

All women, whether healthy with or without a family history or increased clinical risk of BC, as well as those already diagnosed with BC.

Male

Intervention

BRCA1/2 germline genetic testing and/or may include another genetic testing (i.e., pathogenic or likely pathogenic variants: BRCA1/2, PALB2, CHEK2, ATM, BARD1, RAD51c/d)

Somatic genetic testing, Single nucleotide polymorphism (SNP)

Comparison

No genetic testing or alternative screening methods

Not Applicable

Outcome

Costs per quality-adjusted life years (QALY), cost per life-years gained, and costs per number of cancer cases averted.

Cost analysis studies (e.g., with costs but no health outcomes)

Study Design

Partial or full economic evaluation such as cost-benefit analysis (CBA), cost-utility analysis (CUA) or/and cost-effectiveness analysis (CEA) as well as cost-minimization analysis (CMA). Studies conducted in randomized controlled trials, case studies, observational studies, or model-based studies were included.

No publication of full-text articles or original data such as systematic literature reviews, commentaries (letters to the editors, editorials), abstracts, and expert review

Language

English language

Other than the English language

Local setting

Low- and middle-income countries

High-income countries

Date of Publication

Until April 2023

May 2023 onwards